Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) trial by Dr Mazzone and colleagues1 found a reduced progression of carotid artery intima-media thickness (CIMT) in patients with type 2 diabetes mellitus taking pioglitazone for 18 months, compared with those taking glimepiride. There was no regression of CIMT in either treatment group.
Giugliano D, Esposito K. Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness. JAMA. 2007;297(12):1315-1317. doi:10.1001/jama.297.12.1315